Full-Time

Drug Safety and Pharmacovigilance Associate Director

Drug Safety and Pharmacovigilance

Updated on 7/16/2026

Celcuity

Celcuity

201-500 employees

Develops targeted cancer therapies and diagnostics

Compensation Overview

$160k - $179k/yr

+ Bonus + Equity

Remote in USA

Remote

Category
Biology & Biotech (1)
Required Skills
Word/Pages/Docs
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

Get referred to Celcuity

Find people who can refer or advise you

Requirements
  • 10+ years of drug safety/pharmacovigilance experience within a sponsor environment or a combination of sponsor and CRO roles
  • Bachelor’s or advanced degree in a life science or healthcare‑related discipline (e.g., MD, RN, PharmD, NP, PhD, MPH)
  • Comprehensive knowledge of global clinical safety regulations, guidelines, and industry best practices
  • Extensive experience working with commercial safety databases (Argus or ARIS-G), electronic data capture systems, and trial master files
  • Demonstrated experience preparing aggregate safety reports for investigational and/or marketed products (e.g., DSURs, PSUR/PBRERs, PADERs) and contributing to IB updates
  • Strong knowledge of MedDRA and WHODrug coding conventions
  • Excellent written and verbal communication skills, with the ability to convey complex information clearly and concisely
  • Strong interpersonal skills with the ability to collaborate effectively across functions and organizational levels
  • Exceptional attention to detail and ability to manage multiple priorities and documentation requirements
  • Strong technical and analytical skills with advanced proficiency in MS Office (Word, Excel, PowerPoint)
  • Ability to work independently or collaboratively, demonstrating sound judgment and decision‑making in a fast‑paced environment
  • Naturally takes initiative, contributing to continuous improvement efforts and proactively identifying opportunities to enhance processes within the department
  • Continuous improvement mindset with a focus on innovation, efficiency, and operational excellence
  • Flexible, adaptable, and committed to maintaining a positive and professional demeanor
Responsibilities
  • Provide leadership and oversight of external safety vendors to ensure high‑quality, timely, and compliant execution of all outsourced safety activities
  • Lead the preparation, authorship, and review of aggregate safety reports (e.g., DSURs, PADERs, line listings) and manage associated timelines and cross‑functional inputs
  • Provide day-to-day direction to the Safety Operations team and communicate program‑level updates to internal and external stakeholders
  • Demonstrate initiative by exploring potential solutions and offering thoughtful recommendations, engaging leadership when additional insight or alignment is needed
  • Oversee the review and assessment of adverse event reports for assigned programs, ensuring appropriate follow‑up and timely expedited reporting in accordance with global regulatory requirements
  • Contribute to the development, implementation, and continuous improvement of SOPs, work instructions, templates, and systems to ensure compliance with global clinical trial regulations and industry best practices
  • Ensure procedural deviations are documented, investigated, and addressed through effective corrective and preventive actions
  • Support inspection readiness activities and serve as a key contributor during audits and global health authority inspections
  • Develop and maintain study‑specific safety management plans and related documents, ensuring clear delineation of responsibilities between Celcuity and CRO partners
  • Ensure adherence to Safety Data Exchange Agreements and compliance with all agreed‑upon reporting requirements and timelines
  • Review and provide expert input on safety‑related sections of clinical documents, including protocols, charters, Investigator Brochures, and Informed Consent Forms
  • Develop, monitor, and interpret key performance indicators and metrics for internal teams and external vendors to evaluate performance and drive continuous improvement
  • Serve as the safety subject matter expert for internal teams and external stakeholders, providing guidance on safety operations, regulatory expectations, and best practices
  • Perform other tasks as required to assist in company and departmental activities

Celcuity develops targeted cancer therapies and companion diagnostics for solid tumors. Its CELsignia platform is a functional cellular analysis tool that identifies cancer subtypes and predicts how well a patient will respond to a given targeted treatment. Treatments and diagnostics are developed together to guide oncologists in prescribing drugs to patients most likely to benefit, starting with Gedatolisib for breast cancer. The company differentiates itself by using functional cellular analysis to personalize therapy selection rather than relying solely on traditional genetic information, aiming to improve treatment outcomes. Celcuity’s overarching goal is to advance personalized medicine in oncology by matching therapies with the right patients through its integrated drug and diagnostic programs.

Company Size

201-500

Company Stage

IPO

Headquarters

Minneapolis, Minnesota

Founded

2012

Get referred to Celcuity

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • 76% reduction in disease progression or death risk in Phase 3 VIKTORIA-1 triplet therapy trial
  • Secured $500 million convertible notes in June 2026 funding commercialization through 2027 and beyond
  • Targets $10+ billion market serving over 130,000 PIK3CA wild-type breast cancer patients globally

What critics are saying

  • IV administration reduces patient adherence compared to oral CDK4/6 alternatives, limiting first-line uptake
  • Convertible note dilution triggers at $124.53/share amid current $112-$114 trading within 12-24 months
  • FDA could revoke approval or restrict label due to unexpected toxicity in PIK3CA wild-type cohort within 6-12 months

What makes Celcuity unique

  • First FDA-approved pan-PI3K/mTOR inhibitor for HR+/HER2- breast cancer without PIK3CA mutations
  • Proprietary CELsignia platform enables functional cellular analysis to predict targeted therapy effectiveness
  • Combines companion diagnostics with therapeutics to ensure drugs reach patients most likely to benefit

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Paid Vacation

Paid Holidays

Performance Bonus

Company Equity

Growth & Insights

Headcount

6 month growth

-10%

1 year growth

-10%

2 year growth

-7%